Dr. Fleur-Lominy on Targeted Pathways in MPNs

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, discusses targeted pathways in myeloproliferative neoplasms (MPNs).

Some pathways are being targeted in the realm of MPNs, says Fleur-Lominy. More JAK1/2 inhibitors that are proving to be more selective, as was observed with fedratinib (Inrebic); however, others are also being tested. Epigenetic modulators are also available for these patients. Many pathways dependent or independent of STAT downstream are being targeted with therapies that are showing promising results, as well, adds Fleur-Lominy. Some of these therapies are being tested as single agents and others are being tested in combination with ruxolitinib (Jakafi), concludes Fleur-Lominy.